ID16927A - Suspensi berair dari ester asam lemak 9-hidroksirisperidon - Google Patents
Suspensi berair dari ester asam lemak 9-hidroksirisperidonInfo
- Publication number
- ID16927A ID16927A IDP971649A ID971649A ID16927A ID 16927 A ID16927 A ID 16927A ID P971649 A IDP971649 A ID P971649A ID 971649 A ID971649 A ID 971649A ID 16927 A ID16927 A ID 16927A
- Authority
- ID
- Indonesia
- Prior art keywords
- hydroxirirperperonone
- suspension
- water
- fatty acid
- fatty
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96201429 | 1996-05-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ID16927A true ID16927A (id) | 1997-11-20 |
Family
ID=8224016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IDP971649A ID16927A (id) | 1996-05-20 | 1997-05-19 | Suspensi berair dari ester asam lemak 9-hidroksirisperidon |
Country Status (38)
Country | Link |
---|---|
US (1) | US6077843A (bg) |
EP (1) | EP0904081B1 (bg) |
JP (1) | JP3274687B2 (bg) |
KR (1) | KR100358373B1 (bg) |
CN (1) | CN1093762C (bg) |
AR (1) | AR007194A1 (bg) |
AT (1) | ATE208619T1 (bg) |
AU (1) | AU715572B2 (bg) |
BG (1) | BG62684B1 (bg) |
BR (1) | BR9706824B8 (bg) |
CA (1) | CA2236691C (bg) |
CY (2) | CY2270B1 (bg) |
CZ (1) | CZ291284B6 (bg) |
DE (2) | DE122011100027I1 (bg) |
DK (1) | DK0904081T3 (bg) |
EA (1) | EA000536B1 (bg) |
EE (1) | EE03594B1 (bg) |
ES (1) | ES2167745T3 (bg) |
FR (1) | FR11C0035I2 (bg) |
HK (1) | HK1017852A1 (bg) |
HR (1) | HRP970276B1 (bg) |
HU (2) | HU224025B1 (bg) |
ID (1) | ID16927A (bg) |
IL (1) | IL124551A (bg) |
LU (1) | LU91842I2 (bg) |
MX (1) | MX9804816A (bg) |
MY (1) | MY126302A (bg) |
NO (2) | NO315931B1 (bg) |
NZ (1) | NZ330369A (bg) |
PL (1) | PL188309B1 (bg) |
PT (1) | PT904081E (bg) |
SI (1) | SI0904081T1 (bg) |
SK (1) | SK284013B6 (bg) |
TR (1) | TR199800923T2 (bg) |
TW (1) | TW487572B (bg) |
UA (1) | UA61898C2 (bg) |
WO (1) | WO1997044039A1 (bg) |
ZA (1) | ZA974331B (bg) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA72189C2 (uk) * | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
EP1056443B1 (en) * | 1998-02-25 | 2004-05-06 | Abbott Laboratories | Butorphanol sustained release formulations |
AU5489299A (en) | 1998-08-18 | 2000-03-14 | Sepracor, Inc. | Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine |
ES2255490T3 (es) | 1999-03-31 | 2006-07-01 | Janssen Pharmaceutica N.V. | Almidon pregelatinizado en una formulacion de liberacion controlada. |
US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
KR20080028513A (ko) * | 2000-08-14 | 2008-03-31 | 테바 파마슈티컬 인더스트리즈 리미티드 | 리스페리돈의 제조 |
US7666445B2 (en) * | 2000-10-20 | 2010-02-23 | The Trustees Of The University Of Pennsylvania | Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use |
GB0216416D0 (en) * | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
KR100699516B1 (ko) * | 2002-07-29 | 2007-03-26 | 알자 코포레이션 | 팔리페리돈의 조절 전달을 위한 방법 및 복용 형태 |
US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
GB0322994D0 (en) * | 2003-10-01 | 2003-11-05 | Novartis Ag | Organic compounds |
SI1675573T2 (sl) | 2003-10-23 | 2012-08-31 | Otsuka Pharma Co Ltd | Sterilna injektibilna aripiprazolna formulacija z nadzorovanim sproščanjem in postopek |
US8329203B2 (en) * | 2004-01-12 | 2012-12-11 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
US20080305140A1 (en) * | 2004-01-12 | 2008-12-11 | University Of Pennsylvania | Long-Term Delivery Formulations and Methods of Use Thereof |
US8221778B2 (en) | 2005-01-12 | 2012-07-17 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
ES2245252B1 (es) * | 2004-06-15 | 2007-03-01 | Farmalider, S.A. | Solucion acuosa de risperidona para administracion oral. |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
EP1879890A1 (en) | 2005-04-25 | 2008-01-23 | Janssen Pharmaceutica N.V. | Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester |
PL116330U1 (en) * | 2005-10-31 | 2007-04-02 | Alza Corp | Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation |
WO2008021133A2 (en) | 2006-08-09 | 2008-02-21 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies |
WO2008128436A1 (en) * | 2007-04-19 | 2008-10-30 | Youxin Li | Novel compounds for treatment of psychotic disorders, preparation methods and uses thereof |
WO2008133908A2 (en) | 2007-04-23 | 2008-11-06 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
US20090076035A1 (en) * | 2007-09-15 | 2009-03-19 | Protia, Llc | Deuterium-enriched paliperidone |
DK2234617T3 (da) * | 2007-12-19 | 2021-05-25 | Janssen Pharmaceutica Nv | Doseringsskema forbundet med langtidsvirkende injicerbare paliperidonestere |
US20090209757A1 (en) * | 2008-01-10 | 2009-08-20 | Santiago Ini | Processes for the preparation and purification of paliperidone palmitate |
CA2726861C (en) | 2008-02-13 | 2014-05-27 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
EA020299B1 (ru) | 2008-09-04 | 2014-10-30 | АМИЛИН ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Составы с замедленным высвобождением, полученные с применением неводных носителей |
KR102148624B1 (ko) | 2009-09-28 | 2020-08-26 | 인타르시아 세라퓨틱스 인코포레이티드 | 실질 항정상태 약물 전달의 신속 확립 및/또는 종결 |
NZ599558A (en) | 2009-10-30 | 2014-09-26 | Janssen Pharmaceutica Nv | Dosing regimen associated with long-acting injectable paliperidone esters |
US20120259116A1 (en) * | 2009-12-17 | 2012-10-11 | Rajiv Kumar | Novel Process for the Preparation of Paliperidone |
TWI577377B (zh) | 2010-09-16 | 2017-04-11 | Viiv醫療保健公司 | 醫藥組合物 |
US9469630B2 (en) | 2010-10-18 | 2016-10-18 | Sumitomo Dainippon Pharma Co., Ltd. | Sustained-release formulation for injection |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
WO2012164582A1 (en) | 2011-05-31 | 2012-12-06 | Ramamohan Rao Davuluri | Preparation of 3-[2-[4-((6-fluoro-1, 2-benzisoxazol-3-yl)-l-piperidinyl)-6, 7, 8, 9-tetrahydro-9-hydroxy-2-methyl-4h-pyrido[ 1, 2-a]-pyrimidin-4-one (paliperidone) and paliperidone palmitate. |
WO2013046225A2 (en) * | 2011-08-10 | 2013-04-04 | Glenmark Generics Limited | Process for the preparation of paliperidone palmitate |
CN102993200B (zh) * | 2011-09-10 | 2016-02-03 | 鲁翠涛 | 帕潘立酮氨基酸酯及其制备方法 |
JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
US10525057B2 (en) | 2013-09-24 | 2020-01-07 | Otsuka Pharmaceutical Co., Ltd. | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
BR112017021383A2 (pt) | 2015-04-07 | 2018-07-03 | Janssen Pharmaceuticals, Inc. | regime de dosagem para doses omitidas de ésteres de paliperidona injetáveis de longa ação |
JP6993235B2 (ja) | 2015-06-03 | 2022-01-13 | インターシア セラピューティクス,インコーポレイティド | インプラントの設置及び撤去システム |
CN109310743A (zh) | 2016-05-16 | 2019-02-05 | 因塔西亚制药公司 | 胰高血糖素受体选择性多肽及其使用方法 |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
IL307966A (en) | 2017-01-03 | 2023-12-01 | Intarcia Therapeutics Inc | Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
MX2023006370A (es) | 2020-11-30 | 2023-08-07 | Janssen Pharmaceutica Nv | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. |
MX2023006366A (es) | 2020-11-30 | 2023-08-07 | Janssen Pharmaceutica Nv | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. |
WO2022111860A1 (en) | 2020-11-30 | 2022-06-02 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
EP4005555B1 (en) | 2020-11-30 | 2024-05-15 | Janssen Pharmaceutica NV | Methods for ensuring resuspension of paliperidone palmitate formulations |
HUP2100259A1 (hu) | 2021-07-07 | 2023-01-28 | Richter Gedeon Nyrt | Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények |
AU2022329095A1 (en) | 2021-08-20 | 2024-04-04 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2000786C (en) * | 1988-11-07 | 1999-01-26 | Cornelus G. M. Janssen | 3-piperidinyl-1,2-benzisoxazoles |
US5254556A (en) * | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
US5158952A (en) * | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
TW376319B (en) * | 1993-04-28 | 1999-12-11 | Janssen Pharmaceutica Nv | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine |
US5650173A (en) * | 1993-11-19 | 1997-07-22 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
ES2236700T3 (es) * | 1993-11-19 | 2005-07-16 | Janssen Pharmaceutica N.V. | 1,2-benzazoles microencapsulados. |
CA2474701C (en) * | 1993-11-19 | 2009-01-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradeable microparticles containing a biologically active agent |
ES2157442T3 (es) * | 1995-06-06 | 2001-08-16 | Aventis Pharma Inc | Derivados de benzoisoxazol y de indazol, utilizados como agentes neurolepticos. |
US5792477A (en) * | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
-
1997
- 1997-05-01 TW TW086105768A patent/TW487572B/zh not_active IP Right Cessation
- 1997-05-12 BR BRPI9706824-1B8A patent/BR9706824B8/pt not_active IP Right Cessation
- 1997-05-12 HU HU9901319A patent/HU224025B1/hu active Protection Beyond IP Right Term
- 1997-05-12 AU AU29559/97A patent/AU715572B2/en not_active Expired
- 1997-05-12 AT AT97923912T patent/ATE208619T1/de active
- 1997-05-12 KR KR10-1998-0703629A patent/KR100358373B1/ko active IP Right Review Request
- 1997-05-12 EP EP97923912A patent/EP0904081B1/en not_active Expired - Lifetime
- 1997-05-12 IL IL12455197A patent/IL124551A/xx not_active IP Right Cessation
- 1997-05-12 US US09/180,659 patent/US6077843A/en not_active Expired - Lifetime
- 1997-05-12 DE DE201112100027 patent/DE122011100027I1/de active Pending
- 1997-05-12 TR TR1998/00923T patent/TR199800923T2/xx unknown
- 1997-05-12 CZ CZ19981401A patent/CZ291284B6/cs not_active IP Right Cessation
- 1997-05-12 EE EE9800136A patent/EE03594B1/xx active Protection Beyond IP Right Term
- 1997-05-12 EA EA199800531A patent/EA000536B1/ru not_active IP Right Cessation
- 1997-05-12 WO PCT/EP1997/002504 patent/WO1997044039A1/en active IP Right Grant
- 1997-05-12 DK DK97923912T patent/DK0904081T3/da active
- 1997-05-12 DE DE69708284T patent/DE69708284T2/de not_active Expired - Lifetime
- 1997-05-12 PL PL97327995A patent/PL188309B1/pl unknown
- 1997-05-12 ES ES97923912T patent/ES2167745T3/es not_active Expired - Lifetime
- 1997-05-12 SK SK620-98A patent/SK284013B6/sk not_active IP Right Cessation
- 1997-05-12 PT PT97923912T patent/PT904081E/pt unknown
- 1997-05-12 SI SI9730272T patent/SI0904081T1/xx unknown
- 1997-05-12 NZ NZ330369A patent/NZ330369A/xx not_active IP Right Cessation
- 1997-05-12 CA CA002236691A patent/CA2236691C/en not_active Expired - Lifetime
- 1997-05-12 CN CN97191494A patent/CN1093762C/zh not_active Expired - Lifetime
- 1997-05-12 JP JP54150097A patent/JP3274687B2/ja not_active Expired - Lifetime
- 1997-05-19 ID IDP971649A patent/ID16927A/id unknown
- 1997-05-19 ZA ZA974331A patent/ZA974331B/xx unknown
- 1997-05-19 MY MYPI97002172A patent/MY126302A/en unknown
- 1997-05-19 AR ARP970102112A patent/AR007194A1/es active IP Right Grant
- 1997-05-20 HR HR970276A patent/HRP970276B1/xx not_active IP Right Cessation
- 1997-12-05 UA UA98052747A patent/UA61898C2/uk unknown
-
1998
- 1998-04-30 NO NO19981984A patent/NO315931B1/no not_active IP Right Cessation
- 1998-05-12 BG BG102443A patent/BG62684B1/bg unknown
- 1998-06-15 MX MX9804816A patent/MX9804816A/es unknown
-
1999
- 1999-07-10 HK HK99102949A patent/HK1017852A1/xx not_active IP Right Cessation
-
2002
- 2002-04-25 CY CY0200021A patent/CY2270B1/xx unknown
-
2011
- 2011-07-20 LU LU91842C patent/LU91842I2/fr unknown
- 2011-08-18 HU HUS1100013C patent/HUS1100013I1/hu unknown
- 2011-08-18 CY CY2011011C patent/CY2011011I2/el unknown
- 2011-08-29 NO NO2011015C patent/NO2011015I2/no unknown
- 2011-09-02 FR FR11C0035C patent/FR11C0035I2/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ID16927A (id) | Suspensi berair dari ester asam lemak 9-hidroksirisperidon | |
ID24981A (id) | Suspensi berair dari ester-ester asam lemak 9-hidroksirisperidon submikron | |
ID15886A (id) | Pembuatan alkil ester secara kontiniu dari asam met-akrilik | |
ID16433A (id) | Penyediaan kontinyu alkil ester dari asam (met)akrilat | |
ID18276A (id) | Metoda pembuatan ester asam lemak | |
PT823895E (pt) | Esteres de acidos gordos como composto bioactivos | |
ID15885A (id) | Pembuatan alkil ester secara kontiniu dari asam met-akrilik | |
ID19514A (id) | Penggunaan dari kondesasi asam formaldehid naftallenasulfat sebagai pembantu pengeringan | |
ID27724A (id) | Penstabil sediaan parmasi dari turunan-turunan asam gamma-aminobutira dan proses pembuatannya | |
DE69922309D1 (de) | Verfahren zur Herstellung von Fettsäureestern | |
ID26359A (id) | Perbaikan proses untuk memperoleh kembali ksanthophil dari zat perekat tepung jagung | |
ID17679A (id) | Penggunaan dari kondensasi asam formaldehid naftalenasulfat sebagai pembantu pengeringan | |
ID21753A (id) | Proses pembuatan asam asetat | |
DE69712890D1 (de) | Herstellung von sorbitan-fettsäureestern als oberflächenaktive stoffe | |
DE69818500D1 (de) | Herstellung von estern | |
ID24863A (id) | Proses pembuatan vinil ester dari butenoligomeran | |
DE59501040D1 (de) | Quaternierte Triethanolaminfettsäureester | |
ATE216359T1 (de) | Sulfonsäureester von duftstoffen | |
DE59913680D1 (de) | Fettsäurepartialester von Polyolen | |
DE59810616D1 (de) | Verfahren zur Herstellung von Saccharosefettsäureestern | |
ID17993A (id) | Pembuatan alkil ester dari asam (meth) akrilik | |
FR2757165B1 (fr) | Ester de l'acide maleimidobenzoique | |
ID22832A (id) | Metode pembuatan asam formilfosfonat | |
ID20291A (id) | Asam-asam oksobutirat tersubstitusi sebagai penghamba-penghambat matriks metaloproteasa | |
DE59812612D1 (de) | Enzymatische Herstellung von regioselektiven Fettsäureestern der Ascorbinsäure |